Abstracts for a conference on trace elements in diet,nutrition, and health: essentiality and toxicity |
| |
Authors: | L Y Shiu C H Liang Y S Huang H M Sheu K W Kuo |
| |
Institution: | (1) Department of Biochemistry, School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan;(2) Department of Cosmetic Science, Chia Nan University of Pharmacy and Science, Chia Nan, Taiwan;(3) Department of Surgery, School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan;(4) Department of Dermatology, National Cheng Kung University, Tainan, Taiwan;(5) Research Center of Herbal Medicines, G&E Herbal Biotechnology, No. 26, Lane 31, Sec. 1, Huan Dong Rd., Tainan Science Park, SinShih, Tainan County, 74146, Taiwan |
| |
Abstract: | Overexpression of HER2/neu is associated with drug resistance and poor outcome in breast cancer. Solamargine (SM), a glycoalkaloid
purified from the herb Solanum incanum, exhibits HER2/neu gene modulation of HER2/neu high-expressing human breast cancer cell line ZR-75-1. SM downregulation
of HER2/neu gene expression was determined by RT-PCR and Southern hybridization. Additionally, the membrane-bound HER2/neu
receptor in highly HER2/neu-expressing breast cancer cells was determined by radioimmunoassay, immunocytochemistry, fluorescent
immunocytochemistry, and flow cytometry. SM significantly decreased the number of HER2/neu receptors on the cell membrane.
Methotrexate (MTX), 5-florouracil (5-Fu), and cisplatin (CDDP) are commonly used for breast carcinoma treatment in clinics;
however, patients with HER2/neu overexpression exhibit resistance to these anticancer drugs. Notably, combination of MTX,
5-Fu, and CDDP with SM individually increased the susceptibility of breast cancer cells to these chemotherapeutic agents.
Experimental results indicated that downregulation of HER2/neu by SM might be an effective strategy for enhancing drug susceptibility
of breast cancer cells expressing high levels of HER2/neu. |
| |
Keywords: | Solamargine HER2/neu Topoisomerase II Methotrexate 5-Fluorouracil Cisplatin |
本文献已被 PubMed SpringerLink 等数据库收录! |
|